Core Viewpoint - Hansoh Pharmaceutical has successfully added two new indications for its innovative drug Amelot® to the updated National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2025) [1] Group 1: Drug Inclusion and Updates - The innovative drug Amelot® has been included for two new indications in the 2025 National Medical Insurance Directory [1] - The drugs Saintrolai® and Hengmu® have all indications renewed for inclusion in the 2025 National Medical Insurance Directory [1] - The updated National Directory will officially take effect on January 1, 2026 [1] Group 2: Ongoing Agreements and New Additions - The innovative drugs Fumarate Methanesulfonate Tablets (brand name: Hansoh Xinfeng®), Pegylated Liraglutide Injection (brand name: Fulaimi®), and Inalizumab Injection (brand name: Xinyue®) are currently under the National Medical Insurance Directory agreement, valid until December 31, 2026 [1] - The Methanesulfonate Chloride Injection (brand name: Mailinda®) has been included in the regular Category B of the National Medical Insurance Directory [1]